Bionomics CEO believes company has 'significant, unrealized value'
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 07 2024
0mins
Should l Buy ?
Company Developments: Bionomics is undergoing significant changes, including redomiciling to the U.S. and launching Neuphoria Inc., while focusing on their lead asset BNC210, which shows promise in treating anxiety and stress disorders with a novel mechanism of action.
Clinical Progress and Future Plans: The company is preparing for Phase 3 trials for BNC210 in Social Anxiety Disorder (SAD) and PTSD, with expectations for trial initiation by late 2025, while also advancing a partnership with MSD for Alzheimer's treatment that could yield substantial financial benefits.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
